

FABP4 Dynamics in Obesity: Discrepancies in Adipose Tissue and Liver Expression Regarding Circulating Plasma Levels

María Isabel Queipo-Ortuño^{1,2,3}, Xavier Escoté^{3,4,5}, Victoria Ceperuelo-Mallafre^{1,4}, Lourdes Garrido-Sanchez^{3,4}, Merce Miranda^{3,4}, Mercedes Clemente-Postigo¹, Rafael Pérez-Pérez^{2,5}, Belen Peral^{2,5}, Fernando Cardona^{1,2}, Jose Manuel Fernández-Real^{2,6}, Francisco J. Tinahones^{2,7*}, Joan Vendrell^{3,4}

1 Laboratorio de Investigaciones Biomédicas del Hospital Virgen de la Victoria (Fundación IMABIS), Málaga, Spain, **2** CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain, **3** Endocrinology and Diabetes Unit, Joan XXIII University Hospital, IISPV, Universitat Rovira i Virgili, Tarragona, Spain, **4** CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain, **5** Instituto de Investigaciones Biomédicas, Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC) & Universidad Autónoma de Madrid (UAM), Madrid, Spain, **6** Diabetes, Endocrinology and Nutrition Service, Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain, **7** Servicio Endocrinología y Nutrición del Hospital Universitario Virgen de la Victoria, Málaga, Spain

Abstract

Background: FABP4 is predominantly expressed in adipose tissue, and its circulating levels are linked with obesity and a poor atherogenic profile.

Objective: In patients with a wide BMI range, we analyze FABP4 expression in adipose and hepatic tissues in the settings of obesity and insulin resistance. Associations between FABP4 expression in adipose tissue and the FABP4 plasma level as well as the main adipogenic and lipolytic genes expressed in adipose tissue were also analyzed.

Methods: The expression of several lipogenic, lipolytic, PPAR family and FABP family genes was analyzed by real time PCR. FABP4 protein expression in total adipose tissues and its fractions were determined by western blot.

Results: In obesity FABP4 expression was down-regulated (at both mRNA and protein levels), with its levels mainly predicted by ATGL and inversely by the HOMA-IR index. The BMI appeared as the only determinant of the FABP4 variation in both adipose tissue depots. FABP4 plasma levels showed a significant progressive increase according to BMI but no association was detected between FABP4 circulating levels and SAT or VAT FABP4 gene expression. The gene expression of FABP1, FABP4 and FABP5 in hepatic tissue was significantly higher in tissue from the obese IR patients compared to the non-IR group.

Conclusion: The inverse pattern in FABP4 expression between adipose and hepatic tissue observed in morbid obese patients, regarding the IR context, suggests that both tissues may act in a balanced manner. These differences may help us to understand the discrepancies between circulating plasma levels and adipose tissue expression in obesity.

Citation: Queipo-Ortuño MI, Escoté X, Ceperuelo-Mallafre V, Garrido-Sanchez L, Miranda M, et al. (2012) FABP4 Dynamics in Obesity: Discrepancies in Adipose Tissue and Liver Expression Regarding Circulating Plasma Levels. PLoS ONE 7(11): e48605. doi:10.1371/journal.pone.0048605

Editor: Michael Müller, Wageningen University, The Netherlands

Received: May 17, 2012; **Accepted:** September 27, 2012; **Published:** November 5, 2012

Copyright: © 2012 Queipo Ortuño et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by Fondo de Investigación Sanitaria (FIS) 07/1024, 08/1195, CB06/03/0018, CP07/0095 and PI081655, 10/00967, 11/00085 from the Spanish Instituto de Salud Carlos III (ISCIII), Ministerio de Sanidad y Consumo; with the participation of the European Regional Development Fund (ERDF) SAF-2009-10461 from the Ministerio de Economía y Competitividad (MICINN), the Servicio Andaluz de Salud (PI325/2008) and Fundación Mutua Madrileña, Spain (BP). LGS and VCM are supported by fellowships from the Juan de la Cierva programme (JdIC) (JCI200904086 and JCI-2010-06395). CIBERs are an ISCIII Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: fjtinahones@hotmail.com

These authors contributed equally to this work.

Introduction

Cytoplasmic fatty-acid-binding proteins (FABPs) are proteins with a tissue-specific distribution implicated in cellular uptake and transport of fatty acids as well as coordination of metabolic and inflammatory pathways and modulation of gene expression [1,2]. FABP4 is highly expressed in adipose tissue and also expressed in macrophages; it is one of the most abundant proteins in mature adipocytes [3] and is also detected at high concentrations in

human serum [4,5]. Although the biological role of FABP4 is not yet well understood, its function has been linked to insulin sensitivity, lipid metabolism and inflammation [6]. Recently, FABP4 has emerged as an important mediator in the crosstalk between adipocytes and macrophages in adipose tissue. Animal studies have shown that FABP4 knock-out mice are protected from the development of obesity-induced IR, impaired glucose tolerance and atherosclerosis, and their adipocytes have reduced lipolysis effectiveness [7,8]. FABP4 $-/-$ mice in an apo E $-/-$

background show delayed development of arteriosclerotic plaques [9].

Others studies have shown that FABP4 plasma concentrations are increased in patients with obesity, metabolic syndrome (MS), type 2 diabetes (T2D), familial combined hyperlipidemia, lipodystrophy syndromes and cardiovascular disease [10–15]. Moreover, there is an increasing evidence based on population studies supporting the predictive role of increased serum FABP4 for MS and cardiometabolic risk. In cross-sectional studies including overweight or moderately obese patients, FABP4 was closely associated with obesity and MS [5,16]. Furthermore, in others prospective studies FABP4 levels are considered an early marker of metabolic risk for metabolic syndrome development and T2D [4,17,18]. These findings suggest that circulating FABP4 could promote inflammation, mediate insulin resistance, type 2 diabetes and atherosclerosis. In addition, FABP4 could be a potential target for treating metabolic diseases [19].

On the other hand, metabolic and functional differences between adipose tissue depots (subcutaneous (SAT) and visceral (VAT)) may be determinant in the development of obesity and related disorders [20,21]. Some differences in lipogenic, lipolytic and adipokine gene profiles between the two depots have been reported in human studies [22]. Furthermore, several studies have shown a higher gene expression of FABP4 in the SAT than in the VAT of obese subjects [23,24]. However, other authors failed to find a significant difference between FABP4 gene expression in SAT and VAT [25]. In a recent study that we have carried out, we have found that FABP4 gene expression was significantly lower in the morbidly obese group than in obese and lean subjects in the VAT and in the SAT [26]. However, no data are yet available about FABP4 concerning both adipose tissue depots and the liver. More recently, targeted deletion of certain FABPs in murine models has revealed that FABP4 and FABP5 deficient mice are protected against diet-induced obesity, insulin resistance, type 2 diabetes, and a fatty liver, implying that these proteins may play a role in regulating liver fat [27].

We hypothesized that FABP4 may have an important role in the metabolic balance of the adipose and liver tissue in obesity. The aim of this study was to analyze the *FABP4* expression in paired samples of SAT and VAT and hepatic tissues in the context of obesity and IR in patients with a wide BMI range. We also determined the possible relationships between the SAT and VAT *FABP4* expression and the FABP4 plasma level as well as the main adipogenic and lipolytic genes expressed in adipose tissue.

Methods and Procedures

Ethics Statement

Human samples. Appropriate Institutional Review Board approval and adequate Biobank written informed consent were obtained from all the participants. The ethics committees of the corresponding hospitals (Joan XXIII University Hospital (Tarragona, Spain) and Virgen de la Victoria Hospital (Malaga, Spain)) reviewed and approved the experimental protocols.

Animal samples. All animal studies were conducted in accordance with the ethical guidelines for the care and use of laboratory animals of the National Institutes of Health. The protocol was approved by the ethics committee of the Virgen de la Victoria Hospital (Malaga, Spain).

Processing and Selection of Human Study Samples

Between January 2010 and January 2011, two hundred forty-eight subjects were assessed by the endocrinology and surgery departments at Joan XXIII University Hospital (Tarragona,

Spain) and Virgen de la Victoria Hospital (Malaga, Spain). All patients who met the inclusion criteria were recruited to carry out this study. Bio-banking samples included total adipose tissue from subcutaneous and visceral origin, liver tissue, serum and plasma. All the patients had fasted overnight, at least 12 hours before the surgical procedure. Blood samples were collected before the surgical procedure from the antecubital vein, 20 ml of blood with EDTA (1 mg/ml) and 10 ml of blood in silicone tubes. 15 ml of collected blood was used for plasma separation. Plasma and serum samples were stored at -80°C until analytical measurements were performed. EDTA collected blood was used to determine HbA1c. VAT and SAT samples from the same individual were obtained during the surgical procedure. Adipose tissue samples were collected and washed in PBS 1X, immediately frozen in liquid nitrogen and stored at -80°C .

Samples were selected according to stratification by age, gender and BMI (categorized using the World Health Organization criteria) [28]. A first cohort of 62 subjects with a body mass index (BMI) range of 19.82 to 38.54 Kg/m^2 recruited before cholecystectomy or surgery for abdominal hernia was selected from the Joan XXIII University Hospital biobank. A second cohort of 12 lean subjects (BMI <25) recruited before cholecystectomy and 40 morbidly obese subjects recruited before bariatric surgery were selected for the study from the Virgen de la Victoria Hospital biobank. The morbidly obese subjects were stratified according to their IR index (HOMA-IR) as high-grade IR (MO-IR; HOMA-IR>8), or non IR (MO non-IR; HOMA-IR<4.7). The cut-off point for the HOMA-IR was taken from previous studies carried out in a healthy population with no carbohydrate metabolism disorders [29].

All the subjects were of Caucasian origin and reported that their body weight had been stable for at least 3 months before the study. They had no systemic disease other than obesity, and all had been free of any infections during the month before the study. Primary cardiovascular disease, arthritis, acute inflammatory disease and renal diseases were specifically excluded by biochemical work-up. Patients on lipid-lowering drugs were excluded from this study. Smoking habits and alcohol consumption were measured using a standardized questionnaire. All the experiments described below were performed blindly.

Anthropometric Measurements

The height was measured to the nearest 0.5 cm and the body weight to the nearest 0.1 kg. The BMI was calculated as weight (kilograms) divided by height (metres) squared. The waist circumference was measured midway between the lowest rib margin and the iliac crest [30].

Adipose Tissue Sampling and RNA Extraction

Biopsy samples of VAT (omental) and SAT (anterior abdominal wall) were obtained from all subjects. Samples were obtained during abdominal elective surgical procedures (cholecystectomy, surgery for abdominal hernia or during bariatric surgery). The biopsy samples were washed in physiological saline and immediately frozen in liquid nitrogen. The biopsy samples were maintained at -80°C until analysis. Total RNA isolation from adipose tissues was obtained using RNeasy Lipid Tissue Mini Kit (Qiagen GmbH, Germany) and treated with DNase (RNase-free DNase Set; Qiagen). The RNA concentration was determined by absorbance at 260 nm (A260), and the purity was estimated by determining the A260/A280 ratio with a Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, DE). The integrity of total purified RNA was checked by denaturing agarose gel electrophoresis and ethidium bromide staining.

Liver Biopsy and Total RNA Extraction

In the morbidly obese cohort, wedge biopsies (10–400 mg) were taken when necessary during the bariatric procedure for histopathological assessment. Seventeen biopsies were available for the study. The samples were immediately frozen and stored at -80°C . Frozen tissue samples (200–300 mg) were homogenized in 1 ml of Tripure isolation reagent and RNA extraction was done following the manufacturer's instructions (Roche Applied Science). The RNA concentration and purity were determined in the same way as explained for the adipose tissue above.

Adipose Tissue Fractionation

Fresh adipose tissue was finely diced into small pieces (10–30 mg), washed in PBS and incubated in Medium 199 (Gibco) plus 4% BSA and 2 mg/mL of collagenase Type I (Sigma-Aldrich) for 1 h in a shaking water bath at 37°C . Mature adipocytes were separated by filtration through a 200 μm mesh fabric (Spectrum Laboratories, Rancho Dominguez, CA, USA) and by centrifugation for 5 min at 1500 g. The mature adipocytes were removed from the top layer and the pellet consisted of stromovascular cells. Cells were washed 4 times in PBS. Total RNA from isolated adipocytes and from the stromovascular fraction (SVF) was extracted as in [31].

Analytical Methods

Serum glucose, cholesterol, HDL cholesterol, triglycerides (Randox Laboratories Ltd., Antrim, UK) and free fatty acids (FFA) (Wako Bioproducts, Richmond, VA, USA) were measured using standard enzymatic methods. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula. The insulin was analyzed using an immunoradiometric assay (IRMA) (BioSource International, Camarillo, CA, USA), showing a 0.3% cross-reaction with proinsulin. The intra- and inter-assay CV were 1.9% and 6.3%, respectively. The homeostasis model assessment of insulin resistance (HOMA-IR index) was determined as glucose (mmol/L) \times insulin (mIU/L)]/22.5 [16]. Plasma FABP4 levels were measured by sandwich enzyme-linked immunosorbent assay (BioVendor Laboratory Medicine, Inc Palackeho, Czech Republic). The sensitivity was 0.2 ng/mL. The intra- and inter-assay coefficients of variation were 5.8% and 14.7%, respectively.

Gene Expression Relative Quantification in Human Samples

For first-strand cDNA synthesis, a constant amount of 1 μg of total RNA was reverse transcribed using random hexamers as primers and Transcriptase Reverse Transcriptase (Roche, Mannheim, Germany). mRNA levels were assessed by real-time PCR using an Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, Darmstadt, Germany) with TaqMan technology. The reaction was performed, following the manufacturer's protocol, in a final volume of 25 μl . The cycle program consisted of an initial denaturing of 10 min at 95°C , then 40 cycles of 15-s denaturing phase at 95°C , and 1 min annealing and extension phase at 60°C . The commercially available and prevalidated TaqMan primer/probe sets used for human samples were as follows: *GAPDH* (4326317E, RefSeq. NM_002046.3) and β -*Actin* (4352935E, RefSeq. NM_001101.2) used as endogenous controls for the target gene in each reaction of samples from liver and adipose tissue, respectively. We analyzed the mRNA expression levels in SAT and VAT of peroxisome proliferator-activated receptors (*PPAR α* , (Hs00947539_m1, RefSeq NM_001001928.2), *PPAR δ* (Hs00234592_m1, RefSeq NM_005037.5) and *PPAR γ*

(Hs00234592_m1, RefSeq NM_138712); hormone-sensitive lipase (*HSL*) (Hs00193510_m1, RefSeq NM_005357); adipose triglyceride lipase (*ATGL*) (Hs00386101_m1, RefSeq NM_020376); acyl-CoA synthetase short-chain family member 2 (*ACSS2*) (Hs01120921_g1 RefSeq NM_001242393.1); CD36 molecule (*CD36*) (Hs01567185_m1, RefSeq NM_000072.3); Adiponectin (*APM*) (Hs00605917_m1 RefSeq NM_004797); diacylglycerol-O-acyltransferase 1 (*DGAT1*) (Hs01017541_m1, RefSeq NM_012079.4); diacylglycerol-O-acyltransferase 2 (*DGAT2*) (Hs01045913_m1, RefSeq NM_032564.3) and perilipin (*PLIN*) (Hs01106925_m1, RefSeq NM_001145311.1); fatty acid-binding protein 1, 4 and 5, (*FABP4*) (Hs01086177_m1, RefSeq. NM_001442.2), *FABP5* (Hs02339439_g1, RefSeq. NM_001444.1) and *FABP1* (Hs00155026_m1, RefSeq. NM_001443.1)). In liver samples we only analyzed the mRNA levels of *FABP 1*, 4 and 5. In the isolated adipocytes and SVF we analyzed the mRNA level of *FABP4*. A threshold cycle (Ct value) was obtained for each amplification curve and a ΔCt value was first calculated by subtracting the Ct value for the corresponding endogenous control cDNA from the Ct value for each sample and transcript. Fold changes compared with the endogenous control were then determined by calculating $2^{-\Delta\text{Ct}}$, and expression results are given as the expression ratio relative to *GAPDH* or β -*Actin* gene expression, according to the manufacturer's guidelines. All samples were quantified in duplicate and positive and negative controls were included in all the reactions.

Western Blot Assays

Total proteins from adipose tissue samples were extracted by NE-PER Nuclear and Cytoplasmic Extraction Reagents protocol (Pierce). Protein extracts (30 μg) were separated by SDS-PAGE, blotted onto a PVDF membrane and then incubated with anti-human FABP4 antibody at 1:1000 dilution (Santa Cruz Biotechnology, CA, USA) and developed with Super-Signal[®] West Femto/Pico Maximum Sensitivity Substrate (Pierce, Rockford, IL, USA). Protein signals were visualized by electrochemiluminescence using Quantity One[®] software (Bio-Rad Laboratories). Data were normalized to the corresponding β -actin band intensities.

Immunofluorescence

Five-micron sections of frozen adipose tissue were fixed with paraformaldehyde 4%. Staining was performed overnight at 4°C with anti FABP4 antibody at 1:200 dilution, and anti CD68 at 1:25 dilution, washed, and visualized using AF546 and AF488 antibodies at 1:500 dilution (Molecular Probes Inc, OR, USA), respectively. As a negative control, the entire immunofluorescence procedure was performed in the absence of primary antibody. The slides were counterstained with DAPI.

Immunohistochemistry

Sections of formalin-fixed paraffin-embedded adipose tissue were deparaffinised and rehydrated prior to antigen unmasking by boiling in 1 mM EDTA, pH 8. Sections were blocked in normal serum and incubated overnight with anti-human FABP4 antibody at 1:200 dilution, and anti CD68 (Santa Cruz Biotechnology) at 1:25 dilution. Secondary antibody staining was performed using the VECTASTAIN ABC kit (Vector laboratories, Inc. Burlingame, CA) and detected with diaminobenzidine (DAB, Vector Laboratories). Sections were counterstained with haematoxylin prior to dehydration and coverslip placement. As a negative control, the entire immunohistochemical procedure was performed on adjacent sections in the absence of primary antibody.

Studies in Animals

Adult wild-type mice (WT) (8 males and 8 females) and ob/ob mice (8 males and 8 females) C57BL6 were purchased from Jackson Laboratory (The Jackson Laboratory, Bar Harbor, ME). All mice were housed under standard housing conditions on a 12-h light/dark cycle in humidity and temperature-controlled rooms (22°C) and fed ad libitum standard chow diet (RM3, with 11.5% of calories from fat; SDS, Essex, U.K.) during two weeks. The animals were killed after 12 hours of fasting and VAT and liver samples were immediately excised, frozen in liquid nitrogen and stored at -80°C until its analysis.

RNA Extraction and Gene Expression Relative Quantification in Animal Samples

The RNA isolation from VAT and liver tissue and the posterior gene expression analysis by real-time PCR in these mice samples were carried out as described above for the human samples. The commercially available and pre-validated TaqMan primer/probe sets used for real-time PCR were as follows: *GAPDH* (4352339E; RefSeq. NM_008084.2) and *β-Actin* (4352341E; RefSeq. NM_007393.1) as endogenous controls for the target gene in each reaction of samples from liver and adipose tissue, respec-

tively, *FABP4* (Mm00445880_m1, RefSeq. NM_024406.2) and *FABP1* (Mm00444340_m1, RefSeq. NM_017399.4).

Statistical analysis. Statistical analysis was performed by using the SPSS software v.15 (SPSS, Chicago, IL). Normal distributed data are expressed as mean values (standard deviation, SD), and variables with a non-Gaussian distribution are expressed as median (InterQuartil Range, IQR). Discrete variables are expressed as frequency. For statistical analysis of expression variables that did not have a Gaussian distribution, values were logarithmically transformed or analyzed by non-parametrical tests. Differences between more than two groups were compared by using ANOVA with a *post hoc* Bonferroni correction. Differences between depots were analyzed by the Wilcoxon nonparametric test with a *Post-hoc* Bonferroni correction. Differences between groups according to smoking and alcohol consumption status were analyzed using the chi-square test. The Mann-Whitney U test was used to determine the differences in the VAT and SAT *FABP4* expression levels between smokers and non-smokers as well as between alcohol consumers and no alcohol consumers. *Post hoc* calculation showed that the selected sample size for the cohort 1 and the cohort 2 had a 98% and 97% power respectively for detecting a

Table 1. Characteristics of the population, circulating *FABP4* levels and *FABP4* expression levels in cohort 1.

	Cohort 1		
	Lean	Overweight	Obese
	BMI<25 n = 19	25≤BMI<30 n = 28	30≤BMI<35 n = 15
Age (years)	51.7±16.0	57.1±15.0	57.4±12.8
Gender (male)	13 (68.4%)	16 (57.1%)	9 (60.0%)
BMI (kg/m ²)	23.6 (22.1–24.2)	27.2 (26.5–27.9)*	32.1 (30.8–33.6)*#
Waist (cm)	83.0 (79.0–90.0)	97.0 (90.5–100.0)*	107.0 (100.0–117.2)*#
SBP (mmHg)	120 (120–127)	130 (121–140)	145 (130–160)* [§]
DBP (mmHg)	70 (60–80)	70 (70–80)	80 (78–90) [†]
Cholesterol (mM)	5.2±1.2	4.9±1.0	5.2±0.8
HDL-C (mM)	1.5±0.5	1.3±0.3	1.4±0.3
Triglycerides (mM)	1.0 (0.7–1.6)	1.1 (0.8–1.5)	1.0 (0.7–1.3)
Glucose (mM)	4.8±0.7	5.5±0.5*	5.6±0.5*
Insulin (μIU/ml)	3.4 (2.1–6.7)	4.0 (2.8–7.2)	6.6 (4.5–16.5) [†]
HOMA-IR	0.75 (0.54–1.8)	1.01 (0.52–2.09)	1.60 (1.19–4.79) [†]
Non-smokers	12 (63.1%)	17 (60.7%)	9 (60%)
Current-smokers	7 (36.8%)	11(39.3%)	6 (40%)
None-Alcohol consumption	13 (68.4%)	19 (67.8%)	10 (66.7%)
Alcohol consumption ^a	6 (31.6%)	9 (32.1%)	5 (33.3%)
<i>FABP4</i> (ng/ml)	15.5 (12.2–23.1)	20.0 (15.6–32.9)	28.7 (21.5–44.7) [†]
SAT <i>FABP4</i> mRNA	1.64 (1.4–2.3)	1.36 (1.5–1.6) [†]	1.20 (0.9–1.8) [†]
VAT <i>FABP4</i> mRNA	1.47 (0.6–1.8)	0.93 (0.1–1.4)*	1.47 (0.7–2.3)

BMI, body mass index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HDL-C, HDL cholesterol; HOMA-IR, Homeostasis model assessment of insulin resistance.

^aAlcohol consumption was considered from 0.5–1 drink/day for women and 1–2 drinks/day for men.

Differences vs. Lean: **P*<0.001;

[†]*P*<0.05. Differences vs. Overweight:

#*P*<0.001;

[§]*P*<0.05.

Differences vs. Obese: [†], *P*<0.002. Data are expressed as mean and standard deviation (SD).

for normal variables or median and interquartile range (25th–75th) for non-normally distributed variables. Discrete variables are expressed as frequency.

doi:10.1371/journal.pone.0048605.t001

Table 2. Characteristics of the population, circulating *FABP4* levels and *FABP4* expression levels in cohort 2.

	Cohort 2		
	Lean	Morbid no IR	Morbid IR
	BMI<25	BMI>35	BMI>35
	n = 12	n = 14	n = 26
Age (years)	44.3±11.3	41.8±10.4	41.7±13.8
Gender (male)	6 (50%)	4 (28.6%)	7 (26.9%)
BMI (kg/m ²)	21.2±4.7	45.4±10.3*	55.5±4.1* [§]
Waist (cm)	84.5±11.4	118.1±20.0*	140.3±10.9* [#]
SBP (mmHg)	119±14.9	133±18.9 [†]	147±22.4* [§]
DBP (mmHg)	72±15.7	82±10.6	86±17.0
Cholesterol (mM)	5.1±1.1	5.1±1.2	5.2±1.1
HDL-C (mM)	1.4±0.7	1.3±0.3	1.0±0.6
Triglycerides (mM)	1.1±0.8	1.5±0.9	1.3 (1.0–1.7)
Glucose (mM)	4.6±0.4	5.1±0.6 [†]	5.7±0.9*
Insulin (μU/ml)	3.7±2.5	11.7±4.5*	30.4±13.4* [#]
HOMA-IR	0.97±0.45	2.62±0.92*	8.3±3.8* [#]
Non-smokers	9 (75%)	10 (71.4%)	19 (73%)
Current-smokers	3 (25%)	4 (28.6%)	7 (26.9%)
None- alcohol consumption	8 (66.7%)	9 (64.3%)	17 (65.4%)
Alcohol consumption ^a	4 (33.3%)	5 (35.7%)	9 (34.6%)
<i>FABP4</i> (ng/ml)	14.9±11.9	30.8±10.1*	39.2±11.5* [§]
<i>SAT FABP4</i> mRNA	2.2±0.8	1.6±0.6 [†]	1.2±0.3* [§]
<i>VAT FABP4</i> mRNA	2.0±0.9	1.8±0.9	1.3±0.8 [†]

BMI, body mass index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HDL-C, HDL cholesterol; HOMA-IR, Homeostasis model assessment of insulin resistance. ^aAlcohol consumption was considered from 0.5–1 drink/day for women and 1–2 drinks/day for men. Differences vs. Lean: **P*<0.001; [†]*P*<0.05. Differences vs. Morbid no IR: [#]*P*<0.001; [§]*P*<0.05. Differences vs. Morbid IR: [†]*P*<0.002. Data are expressed as mean and standard deviation (SD). for normal variables or median and interquartile range (25th–75th) for non-normally distributed variables. Discrete variables are expressed as frequency. doi:10.1371/journal.pone.0048605.t002

significant difference (*P*<0.05) between *FABP4* mRNA expression levels according to BMI distribution. Associations between quantitative variables were evaluated by Pearson correlation analysis or Spearman correlation for non-normally distributed variables. The independence of the associations was evaluated by linear regression analysis, adjusting for age and gender. In the first cohort in the SAT and VAT depot, the BMI, HOMA-IR index and mRNA expression of genes for lipid metabolism (*ATGL*, *PLIN*, *CD36*, *ACSS2*, *DGAT*, *HSL* and *FABP5* (only for VAT depot)), *adiponectin* and *PPARs* were selected as independent variables. At the same time, in the second cohort in both adipose tissues, the BMI, plasma insulin, plasma triglyceride levels and HOMA-IR were included as independent variables. Statistical significance occurred if a computed two-tailed probability value was *P*<0.05.

Table 3. Bivariate correlations with *FABP4* adipose tissue gene expression in every depot and anthropometric and metabolic characteristics in the first cohort.

	SAT <i>FABP4</i>		VAT <i>FABP4</i>	
	R	<i>P</i> value	R	<i>P</i> value
Population Characteristics				
BMI	−0.323	0.003	−0.390	0.002
SBP	−0.324	0.018	–	–
HOMA-IR	−0.285	0.023	−0.332	0.030
Insulin	−0.336	0.006	−0.342	0.020
Gene expression				
<i>VAT FABP4</i>	0.453	<0.001	–	–
<i>Adiponectin</i>	0.821	<0.001	0.938	<0.001
<i>ATGL</i>	0.357	<0.001	0.715	<0.001
<i>CD36</i>	0.676	<0.001	0.861	<0.001
<i>ACSS2</i>	0.512	<0.001	0.526	<0.001
<i>DGAT1</i>	0.238	<0.033	0.691	<0.001
<i>DGAT2</i>	–	–	0.515	<0.001
<i>HSL</i>	0.543	<0.001	0.669	<0.001
<i>PLIN</i>	0.434	<0.001	0.808	<0.001
<i>PPARα</i>	0.561	<0.001	0.322	0.003
<i>PPARγ</i>	0.661	<0.001	0.798	<0.001
<i>FABP5</i>	–	–	0.478	<0.001

R, Correlation coefficient. Significant differences *P*<0.05. BMI, body mass index; SBP, Systolic Blood Pressure; HOMA-IR, Homeostasis model assessment of insulin resistance; Peroxisome proliferator-activated receptors (*PPARα*, *PPARδ* and *PPARγ*); hormone-sensitive lipase (*HSL*); adipose triglyceride lipase (*ATGL*); acyl-CoA synthetase short-chain family member 2 (*ACSS2*); *CD36* molecule (*CD36*); *Adiponectin* (*APM*); diacylglycerol-O-acyltransferase 1 (*DGAT1*); diacylglycerol-O-acyltransferase 2 (*DGAT2*) and perilipin (*PLIN*); fatty acid-binding protein 1, 4 and 5 (*FABP4*, *FABP5* and *FABP1*). doi:10.1371/journal.pone.0048605.t003

Results

The main clinical, anthropometrical and analytical characteristics of the two study cohorts are shown in Table 1 and Table 2.

FABP4 Expression in Adipose Depots

SAT and *VAT FABP4* mRNA expression levels were strongly correlated between them (*R* = 0.453; *P*<0.001) (Table 3). In *SAT*, lean subjects showed significantly higher mRNA *FABP4* expression levels than overweight and obese subjects from cohort 1. This trend was confirmed in the morbidly obese subjects from cohort 2. In *VAT*, *FABP4* expression levels showed a U-shaped curve, with higher levels in lean and obese subjects when compared with the overweight group (Table 1). When morbidly obese subjects were analysed, a clear down-regulation in visceral fat was observed, mainly in the MO-IR patients. There were no significant differences in the *SAT* and *VAT FABP4* expression levels between smoking and non-smoking either in cohort 1 or cohort 2 (cohort 1: *P*=0.829 and *P*=0.770 respectively; cohort 2: *P*=0.725 and *P*=0.721 respectively). Likewise, alcohol consumption had no significant effect on the *SAT* and *VAT FABP4* mRNA levels (cohort 1: *P*=0.969 and *P*=0.819; cohort 2: *P*=0.480 and *P*=0.709, respectively). No association was detected between circulating levels and subcutaneous or visceral *FABP4* gene expression. However, *FABP4* plasma levels were positively associated with *VAT FABP5* gene expression (*r*=0.465;




Figure 1. *FABP4* expression is higher in isolated adipocytes (ADI) than in the stromovascular fraction (SVF). (A) *FABP4* mRNA expression levels in ADI and SVF from n = 15 subjects with paired adipose biopsies (ADI vs. SVF, * $P=0.001$). Data are expressed as median and IQR. (B) *FABP4* protein levels in total VAT, and in ADI and SVF fractions, from n = 4 subjects. Data are expressed as mean and SD. (ADI vs. SVF, * $P<0.05$) (C)

Representative blot of *FABP4* protein in total VAT and SAT, and in ADI and SVF fractions. (D) Immunofluorescence detection of *FABP4* (red) and CD68 (green) in VAT. The counterstaining of nuclei (DAPI) is shown in blue. Images are representative of VAT collected from five subjects. (E) Immunohistochemical detection of *FABP4* (brown, right panel) and CD68 (macrophage-specific antigen, middle panel) and negative control (left panel) in VAT. Images are representative of VAT sections collected from five subjects. A: Adipocyte; M: Macrophage. Arrow-heads indicate the specific signal.

doi:10.1371/journal.pone.0048605.g001

$P=0.001$). Furthermore, circulating *FABP4* levels showed a significant progressive increase according to BMI, with higher levels in women and positively associated with BMI, blood pressure, HOMA-IR and FFA (data not shown).

FABP4 mRNA/protein Expression in Total and Adipose Tissue Fractions

A selected number of subjects ranging from lean to obese phenotype were analysed for protein quantification. *FABP4* protein levels in VAT tended to be lower than in SAT. However, these differences did not reach statistical significance.

We examined whether *FABP4* expression in human adipose tissue was mainly due to mature adipocyte cells compared to other cell types from the stromovascular pool. After fractioning fresh adipose tissue, we observed that *FABP4* mRNA was significantly more expressed in the adipocyte fraction (Fig. 1A). Protein expression was confirmed by Western blot analysis (Figs. 1B and 1C) immunofluorescence (Fig. 1D) and immunohistochemistry (Fig. 1E), obtaining similar results to the mRNA expression study. Thus, *FABP4* protein was basically found in mature adipocytes with a lower signal in the SVF. Immunohistochemical and immunofluorescence staining confirmed that the majority of

FABP4 was localized in mature adipocytes. The signal obtained in the SVF was mainly attributed to the macrophage content surrounding the adipocytes, as was shown by CD68 co-localization immunostaining and immunofluorescence (Figs. 1D and 1E).

Relationship between *FABP4* Gene Expression and Adipose Tissue Genes

Associations between SAT and VAT *FABP4* expression levels and genes related with lipid synthesis, FFA transport, lipolysis regulation, lipases, *PPAR* transcription factor family, *adiponectin* and *FABP5* were analysed in the first cohort. The most significant bivariate associations are shown in Table 3. In order to strengthen the independence of these associations as predictors of *FABP4* expression, a multiple regression analysis model was constructed for each depot, including the above-mentioned bivariate correlations, adjusting for age and gender. In the SAT depot model, BMI, the HOMA-IR index and mRNA expression of SAT genes for lipid metabolism (*ATGL*, *PLIN*, *CD36*, *AGSS2*, *DGAT1* and *HSL*), *adiponectin* and *PPARs* were selected as independent variables. The result presented a multiple correlation coefficient (R) of 0.918, and SAT *FABP4* expression was mainly associated positively by *ATGL* ($B=0.551$; $P<0.0001$) and *PPAR α* ($B=0.498$; $P=0.001$) gene expression and inversely by the HOMA-IR index ($B=-0.062$; $P=0.033$). In the VAT model, BMI, HOMA-IR and the gene expression described above, including *FABP5*, were included as independent variables. The model presented an $R=0.964$ and VAT *FABP4* expression was mainly associated by *adiponectin* ($B=0.302$; $P<0.0001$), *ATGL* ($B=0.234$; $P=0.027$) and inversely by the HOMA-IR index ($B=-0.023$; $P=0.005$).

Regarding the second morbidly obese cohort, a multiple linear regression analysis was also carried out to weight the contribution of the bivariate associations previously observed in the SAT and VAT *FABP4* gene expression. The equation was also adjusted for age and gender. Thus, BMI, plasma insulin, plasma triglyceride levels and HOMA-IR were included as independent variables. BMI appeared as the only determinant, explaining nearly 50% of the *FABP4* variation in both adipose tissue depots ($B=-0.384$; $P<0.0001$ and $B=-0.402$; $P=0.002$ in SAT and VAT, respectively).

FABP4 Expression in Liver

The mRNA expression of the *FABP* family (*FABP1*, *FABP4* and *FABP5*) was analysed in liver biopsies from a subgroup of the morbidly obese cohort (Table 4). These subjects were representative of the entire morbidly obese cohort and no differences regarding age, gender or metabolic variables except for the insulin and HOMA-IR index were observed between the groups. The MO-IR group showed a significant higher *FABP1*, *FABP4* and *FABP5* mRNA expression levels than the MO non-IR group ($P<0.05$) (Table 4).

FABP4 Expression in Adipose and Liver Tissues from Animal Models

FABP4 gene expression in the VAT as well as *FABP1* and *FABP4* mRNA level in the liver were analyzed in WT and ob/ob mice subjected to fasting. We found a significantly greater *FABP4* expression in the VAT depot in WT compared to ob/ob mice ($P<0.05$). On the other hand, in the liver we found a significant two-fold increase in *FABP1* expression in WT compared to ob/ob

Table 4. Anthropometric and biochemical characteristics and mRNA expression of *FABP1*, *FABP4* and *FABP5* in a subgroup of morbidly obese and morbidly obese IR patients with liver biopsies.

	Morbid no IR n = 7	Morbid IR n = 10
Age (years)	43.43±8.73	44.30±8.26
Waist(cm)	123.78±13.37	125.90±9.87
Hip (cm)	140.58±8.54	144.75±9.17
BMI (Kg/m ²)	41.76±3.70	45.36±6.47
SBP (mm Hg)	106.42±20.75	114.24±19.31
DBP (mm Hg)	91.42±10.69	87.50±11.36
Insulin (μ IU/ml)	9.15±2.16	25.15±7.26*
Glucose (mM)	5.1±0.6	5.4±0.7
Cholesterol (mM)	5.42±1.2	5.37±2.1
Triglycerides (mM)	1.4±0.4	1.3±0.8
HDL-C (mM)	1.0±0.3	1.1±0.7
LDL-C (mM)	2.6±1.0	2.2±0.7
HOMA-IR	2.09±0.54	6.03±2.18*
<i>FABP4</i> mRNA	0.78±0.48	2.28±1.27*
<i>FABP1</i> mRNA	1.01±0.20	1.63±0.75*
<i>FABP5</i> mRNA	0.25±0.19	1.65±1.28*

Data are mean \pm SD;

*indicates significant differences between the means of the two groups. ($P<0.05$). BMI, body mass index; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; HOMA-IR, Homeostasis model assessment of insulin resistance; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure.

doi:10.1371/journal.pone.0048605.t004




Figure 2. *FABP4* expression in adipose and liver tissues from mice. Fasting mRNA expression of *FABP4* visceral adipose tissue in ob/ob (n = 16) (grey bar) and WT (n = 16) (black bar) mouse. Adipose tissue expression level of the gene was normalized using β -actin. The results are given as the mean \pm SD. * indicates significant differences between the means of the two groups ($P < 0.05$). (B) Fasting mRNA expression levels of hepatic *FABP1* and *FABP4* in ob/ob (n = 16) (grey bar) and WT (n = 16) (black bar) mouse. Hepatic tissue expression levels for each gene were normalized using *GADPH*. The results are given as the mean \pm SD. * indicates significant differences between the means of the two groups ($P < 0.05$). doi:10.1371/journal.pone.0048605.g002

mice ($P < 0.05$). In contrast, the liver *FABP4* mRNA gene expression was significantly higher in ob/ob mice in comparison with WT mice (Fig. 2).

Discussion

In this study we observed an inverse relationship between *FABP4* expression and obesity, with a greater down-regulation with severe IR. Interestingly, *FABP4* circulating levels did not parallel adipose tissue expression. Moreover, the inverse pattern in *FABP4* gene expression observed between adipose and hepatic tissues, regarding the IR context, suggests a complementary regulatory system in which different tissues work in a balanced manner.

Several studies have linked *FABP4* circulating levels with obesity and other diseases [32–36]. These associations suggested that *FABP4* may be involved in the vascular events related with these pathologies [32]. Adipocytes are the main source of *FABP4*, and it would be rational to think than a higher circulating plasma protein

levels, greater adipose tissue expression. However, our study demonstrates an inverse association between obesity and *FABP4* adipose tissue expression. These differences were confirmed in two separate cohorts, strengthening the validity of the observation. A previous study in morbidly obese women found no differences in *FABP4* adipose tissue expression when compared with lean counterparts; however the low number of lean subjects included may have contributed to the discrepancies [37]. Concerning *FABP4* circulating levels, our results failed to find an association with adipose tissue expression.

Fisher et al., demonstrated that adipose tissue expression of *FABP4* was related to circulating non esterified fatty acid levels in obese subjects, which would explain in part the insulin resistant environment observed in obesity [7]. Adipose *FABP4* interacts physically with HSL promoting lipolysis [8]. In fact, we observed that *FABP4* expression was mainly determined by *ATGL*. VAT has a greater lipolytic potential than SAT, and the release of FFA from VAT directly into the portal circulation is one of the mechanisms involved in fatty liver disease and hepatic IR [38].

Viewing the *FABP4* mRNA down-regulation found in obese patients, we are tempted to speculate about a possible adipose tissue dysfunction leading to metabolic disorders. Thus, low *FABP4* expression in adipose tissue could lead to less FFA transport to β -oxidation, resulting in a FFA accumulation, which may exceed the adipose tissue storage capacity, resulting in excess fat “overspilled” to non-adipose tissues such as the liver. In the liver, the initial response is to facilitate the storage in the form of triacylglycerides but the limited capacity becomes saturated. Lipid excess produces toxic reactive species promoting lipotoxicity. These data suggest that a high adipose tissue *FABP4* expression may have a protective role, controlling the availability of FFA and their metabolites in the cytoplasm [39–41]. Of note, in our study the *adiponectin* adipose tissue expression appeared as a positive determinant of *FABP4* expression, a protein with a predominant role in insulin sensitivity with probable anti-inflammatory activity in metabolic diseases. These results are in line with a recent report in which data from DNA microarray-based gene expression profiling showed a progressive down-regulation of genes involved in fatty acid metabolism with increasing fat mass in patients with the metabolic syndrome [42].

Insulin resistance emerged as an important determinant of *FABP4* adipose expression. Hence, when IR increased, *FABP4* expression in adipose tissue decreased. This observation disagrees with the data obtained in several animal studies. Thus, mouse models with genetic disruption of *FABP4* showed a significant improvement in insulin sensitivity despite an increase in body weight, highlighting this protein as an important player in IR mechanisms. However, when the effect of *FABP4* knockdown in adipose tissue was studied, no effect on plasma glucose, insulin sensitivity or lipid homeostasis was observed [43]. These observations may help to explain the absence of increased *FABP4* gene expression in our patients. A possible explanation has been attributed in part to a compensatory expression increase of other FABP proteins, such as *FABP5* in adipose tissue. In fact, *FABP5* mRNA was highly correlated with *FABP4* mRNA in VAT, and with *FABP4* circulating levels, suggesting a possible co-regulatory role between them. Unfortunately, we have no mechanistic studies to unravel the intrinsic regulatory pathways involving IR and *FABP4* regulation in human adipose tissue, but the present data suggest a positive effect of insulin-sensitivity on *FABP4* expression.

We found an significant increased mRNA expression of *FABP1*, *FABP4* and *FABP5* in the liver of morbidly obese-IR patients, which contrasts with the significantly decreased expression of *FABP4* in adipose tissue that we found in the MO-IR patients compared to lean controls. Therefore, we hypothesized that decreased *FABP4* expression in adipose tissue linked to obesity could be compensated by an increased expression of *FABP4* in peripheral tissues with the onset of IR. Thus, this higher *FABP4*

expression found in the liver of MO-IR patients indicates that *FABP4* expression could be a predictor of IR in morbidly obese patients. The same results were found in the animal model studied: VAT *FABP4* expression was also significantly lower in ob/ob mice as compared with WT mice. However, when liver *FABP4* expression was analyzed, we found a significant difference between WT and ob/ob mice, with a more elevated hepatic *FABP4* gene expression in ob/ob mice than in WT mice.

One of the main limitations of our study is its cross-sectional design, which does not permit to infer pathophysiological mechanisms with the observed results. Thus, the obtained results should be interpreted with caution. Moreover, we are aware that the low number of subjects analyzed for protein data and the absence of quantification of the *in vivo* fat mass depots hinder the adequate interpretation of the findings. However, protein and gene expression data were along the same lines. Another limitation was the inability to analyze liver biopsies from lean healthy subjects because of obvious ethical concerns. Finally, we have not taken into account the possible effect of lifestyle factors such as the changes in physical activity of the study subjects on the *FABP4* plasma level, that previously have been described as the main predictors of *FABP4* plasma modifications even after adjusting for body mass index and insulin resistance parameters.

In summary, we observed a decrease in *FABP4* expression in adipose tissue inversely associated with obesity, with the insulin-resistance status being an important determinant involved in the tissue expression. We also found an increased liver expression of *FABP4* in MO-IR patients, suggesting that adipose tissue and liver may act in a balanced manner according to the insulin resistance status. In conclusion, we propose that *FABP4* may have different roles when analysed systemically or locally. Thus, a more global view is necessary to better understand its function. Further prospective experiments are required to confirm these results.

Acknowledgments

The authors wish to thank all the subjects for their collaboration. We also gratefully acknowledge the help of Ian Johnstone for his expertise in preparing this manuscript. The research group belongs to the “Centros de Investigación en Red” (CIBER, CB06/03/0018) of the “Instituto de Salud Carlos III”. We gratefully acknowledge the very useful technical assistance provided by Verónica Alba.

Author Contributions

Conceived and designed the experiments: MIQO BP FC JMFR FJT JV. Performed the experiments: XE VCM LGS MM MCP RPP. Analyzed the data: MIQO XE BP FC JMFR FJT JV. Contributed reagents/materials/analysis tools: MIQO BP FC JMFR FJT JV. Wrote the paper: MIQO XE BP FC JMFR FJT JV VCM LGS MCP.

References

- Coe NR, Bernlohr DA (1998) Physiological properties and functions of intracellular fatty acid-binding proteins. *Biochim Biophys Acta* 1391: 287–306.
- Hertzel AV, Bernlohr DA (2000) The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. *Trends Endocrinol Metab* 11: 175–180.
- Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, et al. (2005) Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. *Cell Metab* 1: 107–119.
- Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, et al. (2007) Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. *Circulation* 115: 1537–1543.
- Xu A, Wang Y, Yu SJ, Stejskal D, Tam S, et al. (2006) Adipocyte fatty acid-binding protein is a plasma biomarker associated with obesity and Metabolic Syndrome. *Clin Chem* 52: 405–413.
- Makowski L, Hotamisligil GS (2004) Fatty acid binding-proteins—the evolutionary crossroads of inflammatory and metabolic responses. *J Nutr* 134: 2464S–2468S.
- Hotamisligil GS, Johnson RJ, Distel RJ, Ellis R, Papanioannou VE, et al. (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. *Science* 274: 1377–1379.
- Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, et al. (2002) Adipocyte fatty acid binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. *Arterioscler Thromb Vas Biol* 22: 1686–1691.
- Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, et al. (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. *Nat Med* 7: 699–705.
- Cabre A, Lázaro I, Cofán M, Jaraúta E, Plana N, et al. (2009) *FABP4* plasma levels are increased in familial combined hyperlipidemia. *J Lipid Res* 51(5): 1173–8.

11. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimón F, et al. (2007) Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. *Atherosclerosis* 195:e150–8.
12. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimón F, et al. (2008) Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. *Clin Chem* 54: 181–7.
13. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimón F, et al. (2008) Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. *J Lipid Res* 49: 1746–51.
14. Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragonés G, et al. (2008) The fatty acid binding protein-4 (*FABP4*) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. *Atherosclerosis* 199: 147–53.
15. Bao Y, Lu Z, Zhou M, Li H, Wang Y, et al. (2010) Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. *PLoS One* 6(4): e19115.
16. Koh JH, Shin YG, Nam SM, Lee MY, Chung CH, et al. (2009) Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. *Diabetes Care* 32: 147–15.
17. Tso A, Xu AW, Sham P, Wat NM, Wang Y, et al. (2007). Serum adipocyte fatty acid-binding protein as a new biomarker predicting the development of type 2 diabetes. *Diabetes Care* 30: 2667–2672.
18. Stejskal D, Karpisek M (2006) Adipocyte fatty acid binding protein in Caucasian population: a new marker of metabolic syndrome?. *Eur J Clin Invest* 36: 621–625.
19. Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. *Nat Rev Drug Discov* 7: 489–503.
20. Després JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. *Nature* 444: 881–887.
21. Klötting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, et al. (2010) Insulin sensitive obesity. *Am J Physiol Endocrinol Metab* 299: 506–515.
22. Miranda M, Escoté X, Ceperuelo-Mallafre V, Alcaide MJ, Simón I, et al. (2010) Paired subcutaneous and visceral adipose tissue aquaporin-7 expression in human obesity and type 2 diabetes: differences and similarities between depots. *J Clin Endocrinol Metab* 95: 3470–3479.
23. Drolet R, Richard C, Sniderman AD, Mailloux J, Fortier M, et al. (2008) Hypertrophy and hyperplasia of abdominal adipose tissues in women. *Int J Obes (Lond)* 32(2): 283–291.
24. Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thörne A, et al. (2001) Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. *Diabetologia* 44(10): 1268–1273.
25. Poulain-Godefroy O, Lecoq C, Pattou F, Frühbeck G, Froguel P (2008) Inflammation is associated with a decrease of lipogenic factors in omental fat in women. *Am J Physiol Regul Integr Comp Physiol* 295(1): R1–7.
26. Clemente-Postigo M, Queipo-Ortuño MI, Fernandez-García D, Gomez-Huelgas R, Tinahones FJ, et al. (2011) Adipose tissue gene expression of factors related to lipid processing in obesity. *PLoS One* 6(9): e24783.
27. Shearer J, Fueger PT, Bracy DP, Wasserman DH, Rottman JN (2005) Partial gene deletion of heart-type fatty acid-binding protein limits the severity of dietary-induced insulin resistance. *Diabetes* 54: 3133–3139.
28. World Health Organization (2000) Obesity: Preventing and Managing the Global Epidemic. In WHO (eds). WHO Technical Report Series 894, Geneva, Switzerland.
29. Garcia-Fuentes E, Murri M, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida JM, et al. (2009) PPAR γ expression after a high-fat meal is associated with plasma superoxide dismutase activity in morbidly obese persons. *Obesity* 18: 952–958.
30. Ceperuelo-Mallafre V, Näf S, Escoté X, Caubet E, Gomez JM, et al. (2009) Circulating and adipose tissue gene expression of zinc-alpha2-glycoprotein in obesity: its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. *J Clin Endocrinol Metab* 94: 5062–5069.
31. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non alcoholic fatty liver disease. *J Clin Invest* 115: 1343–1351.
32. Bagheri R, Lehrke M, Kapoor S, Wolfe M, Terembula K, et al. (2007) Plasma Levels of Fatty Acid Binding Proteins 4 and 5 are Markers of Adiposity and the Metabolic Syndrome but are not Independent Predictors of Subclinical Atherosclerosis in Type 2 Diabetes. *Circulation* 116: 270.
33. Tinahones FJ, Garrido-Sanchez L, Miranda M, Garcia-Almeida JM, Macias-Gonzalez M, et al. (2010) Obesity and Insulin Resistance-Related Changes in the Expression of Lipogenic and Lipolytic Genes in Morbidly Obese Subjects. *Obes Surg* 20: 1559–1567.
34. Shankar SS, Steinberg HO (2005) FFAs: do they play a role in vascular disease in the insulin resistance syndrome?. *Curr Diab Rep* 5: 30–35.
35. Pirro M, Mauriege P, Tchermof A, Cantin B, Dagenais GR, et al. (2002) Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. *Atherosclerosis* 160: 377–384.
36. Roden M (2007) Blocking fatty acids' mystery tour: a therapy for metabolic syndrome?. *Cell Metab* 6: 89–91.
37. Terra X, Quintero Y, Auguet T, Porras JA, Hernández M, et al. (2011) *FABP4* is associated with inflammatory markers and metabolic syndrome in morbidly obese women. *Eur J Endocrinol* 164: 539–547.
38. Moller DE, Kaufman KD (2005) Metabolic syndrome: a clinical and molecular perspective. *Annu Rev Med* 56: 45–62.
39. Zeyda M, Stulnig TM (2009) Obesity, inflammation, and insulinresistance-a mini-review. *Gerontology* 55: 379–386.
40. Slawik M, Vidal-Puig AJ (2007) Adipose tissue expandability and the metabolic syndrome. *Genes Nutr* 2: 41–45.
41. Gaemers IC, Stallen JM, Kunne C, Wallner C, van Werven J, et al. (2011) Lipotoxicity and steatohepatitis in an over fed mouse model for non-alcoholic fatty liver disease. *Biochim Biophys Acta* 1812: 447–458.
42. Klimčáková E, Roussel B, Márquez-Quinones A, Kováčová Z, Kováčiková M, et al. (2011) Worsening of obesity and metabolic status yields similar molecular adaptations in human subcutaneous and visceral adipose tissue: decreased metabolism and increased immune response. *J Clin Endocrinol Metab* 96: 73–82.
43. Yang R, Castriota G, Chen Y, Cleary MA, Ellsworth K, et al. (2011) RNAi-mediated germline knockdown of *FABP4* increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice. *Int J Obes* 35: 217–225.